These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 28758574)

  • 1. Personalized & Precision Medicine in Cancer: A Theranostic Approach.
    Choudhury P; Gupta M
    Curr Radiopharm; 2017 Nov; 10(3):166-170. PubMed ID: 28758574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiated thyroid cancer theranostics: radioiodine and beyond.
    Choudhury PS; Gupta M
    Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
    Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
    [No Abstract]   [Full Text] [Related]  

  • 5. Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.
    Kulkarni HR; Singh A; Langbein T; Schuchardt C; Mueller D; Zhang J; Lehmann C; Baum RP
    Br J Radiol; 2018 Nov; 91(1091):20180308. PubMed ID: 29762048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [PET/CT: Molecular Imaging and Theranostics for Radionuclide Therapy].
    Derlin T; Bengel FM
    Pneumologie; 2017 Jan; 71(1):48-62. PubMed ID: 28114710
    [No Abstract]   [Full Text] [Related]  

  • 7. TheraP: a randomized phase 2 trial of
    Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
    BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
    Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
    Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Imaging and Precision Medicine: PET/Computed Tomography and Therapy Response Assessment in Oncology.
    Sheikhbahaei S; Mena E; Pattanayak P; Taghipour M; Solnes LB; Subramaniam RM
    PET Clin; 2017 Jan; 12(1):105-118. PubMed ID: 27863562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
    Verma P; Malhotra G; Agrawal R; Sonavane S; Meshram V; Asopa RV
    Clin Nucl Med; 2018 Aug; 43(8):e265-e268. PubMed ID: 29894335
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    El-Maouche D; Sadowski SM; Papadakis GZ; Guthrie L; Cottle-Delisle C; Merkel R; Millo C; Chen CC; Kebebew E; Collins MT
    J Clin Endocrinol Metab; 2016 Oct; 101(10):3575-3581. PubMed ID: 27533306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
    Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
    Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An introduction to the clinical practice of theranostics in oncology.
    Turner JH
    Br J Radiol; 2018 Nov; 91(1091):20180440. PubMed ID: 30179054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theranostic in Nuclear Medicine - The paradigm of NET.
    Giammarile F
    Hell J Nucl Med; 2023; 26 Suppl():42-43. PubMed ID: 37658562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear Medicine Imaging Procedures in Oncology.
    Mohan AM; Beindorff N; Brenner W
    Methods Mol Biol; 2021; 2294():297-323. PubMed ID: 33742410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
    Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
    J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Theranostics and hybrid imaging for somatostatin receptor-expressing tumors].
    Werner RA; Bengel FM; Derlin T
    Radiologe; 2020 May; 60(5):413-420. PubMed ID: 32052116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor.
    Acar E; Kaya GÇ
    Clin Nucl Med; 2019 Jan; 44(1):53-54. PubMed ID: 30325820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oncological theranostics in nuclear medicine].
    Laschinsky C; Herrmann K; Fendler W; Nader M; Lahner H; Hadaschik B; Sandach P
    Radiologie (Heidelb); 2022 Oct; 62(10):875-884. PubMed ID: 36112174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT.
    Parida GK; Tripathy S; Datta Gupta S; Singhal A; Kumar R; Bal C; Shamim SA
    Clin Nucl Med; 2018 Apr; 43(4):248-249. PubMed ID: 29474196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.